1Manns MP;McHutchison JG;Gordon SC.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C:a randomised trial[J]The Lancet,2001(9286):958-965. 被引量：4
2Lau GKK;Zhuang H.Top hepatology issue in China,2003. 被引量：2
4Shiffman ML.Retreatment of patients with chronic hepatitis C,2002(zk). 被引量：1
5Hadziyannis SJ;Sette H;Morgan TR.Peginterferon alfa-2a (40 kilodaltons) and ribovirin combination therapy in chronic hepatitis C:randomized study of the effect of treatment duration and ribavirin dose,2004. 被引量：1
6Fried MW;Shiffman ML;Reddy KR.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection[J]New England Journal of Medicine,2002(13):975-982. 被引量：4
7Malcolm BA;Liu R;Lahser F.SCH 503034,a mechanism-based inhibitor of hepatitis C virus NS3 protease,suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells[J],2006(03). 被引量：1
8Afdhal N;Freilich B;Robert Lm'ne.Colchicine versus peg-intron long term (copilot) trial:interim analysis of clinical outcomes at year 2,2004(zk). 被引量：1
9Poynard T;McHutchison J;Davis GL.Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C[J],2000. 被引量：1
10Jacobsen IM;Ahmed F;Russo MW.Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C:a trial in non-responders to interferon monotherapy or combination therapy and in combination therapy relapsers:final results,2003. 被引量：1
二级参考文献17
1Camma C, Bruno S, Schepis F, et al. Retreatment with interferon plus ribavirin of chronic hepatitis C non- responders to interferon monotherapy: a meta- analysis of individual patient data[ J ]. Gut, 2002,51:864-869. 被引量：1
2Papatheodoridis GV, Papadimitropoulos VC, Hsdziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus- reated cirrhosis: a meta- analysis[J] .Aliment Pnarmaool Ther, 2001,15:689- 698. 被引量：1
3Kjaergard LL, Krogsgaard K, Gluud C. Interfern alfa with or without ribavirin for chronic hepatitis C: systematic review of randonmised trials[J].BMJ, 2001,323:1151 - 1155. 被引量：1
4Alberti A, Benvegnu L. Management of hepatitis[J] .J Hepatol, 2003,38(Suppl1): S1014 - S1 18. 被引量：1
5Poynard T, MdHutchison J, Davis GL, et al. Impact of interferon alfa - 2b and ribavirin on progression of liver fibrosiis in patients with chronic hepatitis C[J].Hepatology, 2000,32:1131 - 1137. 被引量：1
6Booth JCL, O' Grady J, Neuberger J. Clinical guidelines on the mangement of hepatitis C[J]. Gut, 2001, 49(Suppl I ): il - i12. 被引量：1
7Chander G, Sulkowski MS, Jenckes MW, et al. Treatment of chronic hepatitis C: a systemic review[J]. Hepatology, 2002, 36(5 Suppl 1 ):S135 - S144. 被引量：1
8Di Ciomm no V, Russo P, Rava L, etal. Interferon alpha in the treatment of chronic hepatitis C in children: a mmeta- analysis[J] .J Viral Hepat,2003,10:210 - 214. 被引量：1
9Fabrizi F, Dulai G, DixitV, et al. Meta- analysis: interfeorn for the treatment of chronic hepatitis C in dialysis patients[J] .Aliment Phamacol Ther, 2003,18:1071 - 1081. 被引量：1
10National Institute of Health Consensus Development Conference Panel Statenent. Management of hepatitis C[J].Hepatology, 2002,36(5 Suppl 1):S3- S20. 被引量：1
